Обоснование. Неонатальный скрининг на врожденный гипотиреоз (ВГ) позволяет своевременно диагностировать забо-левание и начинать заместительную терапию. Аналитические работы в сфере здравоохранения создают основу для при-нятия управленческих решений, в том числе органами государственной власти. Цель исследования -анализ результатов неонатального скрининга на врожденный гипотиреоз в Российской Федерации. Материал и методы. Проанализированы данные отчетов территориальных органов управления здравоохранением (ТОУЗ) о результатах работы медико-генетической службы регионов, ежемесячно предоставляемые в Министерство здравоох-ранения Российской Федерации, в том числе о количестве родившихся детей, обследованных новорожденных и вновь выявленных случаев ВГ. Результаты. Частота выявления ВГ в Российской Федерации по результатам неонатального скрининга составила 1 случай на 3617 новорожденных (максимум 1:2379, минимум 1:4752 в различных федеральных округах). Охват неонатальным скринингом на ВГ в Российской Федерации варьирует по годам и территориям -от 67,9% (в 1997 г.) до 99,8% (в 2012 г.) и от 81,7% (в СКФО) до 99,9% (в ЦФО). При доле охвата новорожденных скринингом свыше 70% каждый следующий процент охвата позволяет выявить 6-7 новых случаев ВГ. Заключение. Проведенный анализ свидетельствует о необходимости дальнейшего изучения особенностей заболеваемости врожденным гипотиреозом в различных регионах Российской Федерации, совершенствования процессов организации неонатального скрининга на ВГ. Background. Neonatal screening for congenital hypothyroidism (CH) allows the timely diagnosis of disease and onset of replacement therapy. Analytical research in the field of health care provides the basis for making managerial decisions, in particular by public authorities. Objective -the study objective was to analyze the results of neonatal screening for congenital hypothyroidism in the Russian Federation. Material and methods. We analyzed reports of local health authorities (LHAs) on the results of activities of regional medical and genetic services, which were monthly submitted to the Ministry of Health of the Russian Federation. The reports included the number of newborns, examined newborns, and newly diagnosed CH cases. Results. According to the results of neonatal screening, the rate of CH detection in the Russian Federation was 1 case per 3,617 newborns (maximum, 1 per 2379; minimum, 1 per 4752 in different federal districts). The coverage of neonatal screening for CH in the Russian Federation varies by years and regions, from 67.9% (1997) to 99.8% (2012) and from 81.7% (North Caucasian Federal District) to 99.9% (Central Federal District). With the percentage of newborn screening coverage more than 70%, each additional coverage percent results in detection of 6-7 new CH cases. Conclusion. The conducted analysis indicates the need for further studying the features of congenital hypothyroidism incidence in different regions of the Russian Federation and improving organizational processes of neonatal screening for CH.
INTRODUCTION
The need for large-scale examination (screening) of newborns for a number of congenital diseases is related to the fact that the fi rst days (weeks) of life are characterized by the lack of a distinctive clinical picture suffi cient for making a diagnosis and starting early treatment of the disease, while detection of the disease during screening facilitates prevention of adverse eff ects on life and health of the child. For the fi rst time in the world, large-scale screening of newborns was conducted in Massachusetts (United States) in 1962: dry blood spots of newborns were used to determine the phenylalanine level and diagnose phenylketonuria (PKU) in the fi rst days of a child's life [1] . Screening of newborns for PKU was a breakthrough in the early diagnosis of hereditary diseases. Techniques for blood sampling and transportation, examination protocol, and organization of laboratory services formed the basis for the development and implementation of neonatal screening for other socially significant diseases, in particular (given the occurrence rate of disease) for congenital hypothyroidism (CH). Screening for CH was fi rst organized and performed in Quebec (Canada) in 1974 by Jean Dussault and Claude Laberge, 15 who determined the T 4 level in dried blood spots on fi lter paper using a radioimmunoassay [2] . Two years later, detection of total T 4 was replaced by detection of blood TSH on the 5th day of life due to a high rate of false negative results [3] . In 1980, screening of newborns for CH was conducted in 36 centers in 12 European countries [4] [5] [6] . By 1992, about 50 million children were examined worldwide, and CH was diagnosed in 1 case of 3,000-4,000 newborns [7] .
Organization, implementation, conducting, and monitoring of screening in any country require the mandatory participation of governmental (and/or non-governmental) organizations that are responsible for rigorous implementation of all stages of large-scale examination. Equal accessibility of the screening procedure for all newborns and permanent control for timely prescription and onset of treatment should be organized. Tests should be conducted in specialized laboratories by trained specialists provided with necessary information and other support. An important aspect that largely aff ects the results and eff ectiveness of screening is public awareness of the screening importance and relevancy.
In Russia, screening for CH was introduced in stages, starting with 1994, initially in single "pilot" regions whose number was constantly increasing. Since 2006, the screening, as part of implementation of the national priority project "Health", has been conducted throughout the country. In 1994, the main document regulating organization and conducting of screening was the Order of the Ministry of Health of the Russian Federation No. 316 of December 30, 1993 "On Further Development of the Medical and Genetic Service of the Ministry of Health of the Russian Federation". Guidelines for screening were released [8, 9] . Currently, screening of newborns in the Russian Federation is carried out in accordance with the Order of the Ministry of Health and Social Development of the Russian Federation No. 185 of March 22, 2006 "On Large-Scale Screening of Newborns for Hereditary Diseases". On the basis of this order, all subjects of the Russian Federation have adopted regional departmental regulatory acts. The organization of screening is regulated based on an order of heads of administrations of subjects of the Russian Federation and municipalities. Issues concerning screening of newborns are also regulated by the Order of the Ministry of Health and Social Development of the Russian Federation No. 409n of June 01, 2010 "Procedure for Provision of Neonatal Medical Care". In 2014, the professional community adopted clinical guidelines (Protocol) for management of children with CH [10] , which were developed based on the experience in monitoring of CH patients in the Russian Federation [11] [12] [13] [14] and around the world [15] .
OBJECTIVE
The study objective was to analyze the results of neonatal screening for CH in the Russian Federation and evaluate the coverage of newborns with screening, depending on the period and region.
MATERIAL AND METHODS

Study design
We performed an observational retrospective study with analysis of statistical data on the results of neonatal screening for CH in the Russian Federation in 1997-2015 (excluding 2005).
Eligibility criteria
The study included statistical reports of local health authorities (LHAs), which provided data on numbers of newborns, examined newborns, and detected CHs for each region of the Russian Federation for an 18-year period (2005 data were excluded from the analysis due to insuffi cient information).
Study conditions
The study was conducted at the Ministry of Health of the Russian Federation (monthly paper reports of LHAs on activities of regional medical and genetic services submitted to the Ministry of Health of the Russian Federation), Higher School of Economics (generation of an electronic database and statistical analysis), and Endocrinology Research Centre of the Ministry of Health of the Russian Federation (conception development, data analysis, and description of the results).
Study duration
The study (collection, processing, and statistical analysis of data) was conducted in 2016.
Study methodology
The data (numbers of newborns, examined newborns, and detected cases of the disease) from annual LHA reports were transferred to the electronic database. Therefore, we analyzed the cumulative sample containing data on the numbers of newborns, examined newborns, and detected CH cases in each subject of the Russian Federation for the 18-year period, from 1997 to 2015 (excluding 2005). From 1997 to 2015, the federal structure of Russia underwent a number of changes [some regions were merged into one subject; two federal districts (FDs) were re-established: the North Caucasian Federal District (split from the Southern Federal District) in 2010 and the Crimean Federal District in 2015]. In this regard, all available indicators were referred to the 2015 federal structure to unify the data. Therefore, a comparative analysis was conducted for 8 federal districts and 83 subjects of the Russian Federation (data for the Crimean Federal District are presented separately and only for 2015). 
Statistical analysis
Statistical data processing was performed using the STATA software package (Stata Corporation, USA). The incidence of CH was calculated for each calendar year, separately for each of the 83 subjects of the Russian Federation, annually for each federal district and for the Russian Federation as a whole. The incidence is presented as 1:X, where X = A:B, with A being the number of examined newborns for one calendar year and B being the number of detected CH cases in the same calendar year.
To study a relationship between the absolute number of detected disease cases and the percentage (%) of newborn screening coverage, we performed a linear regression analysis of panel data using the STATA application software package [16] . The panel data are represented by two-dimensional arrays, one of the array dimensions is a temporary variable (calendar year), and the second is a spatial variable (a subject of the Russian Federation). A model (random eff ects model) was chosen based on the Hausman test. Territorial (federal district) and temporary (4-5-year period) binary variables were included as the so-called fi ctitious variables. The Breusch-Pagan test was used to check the presence of random errors in the regression model. Further, the problem of heteroscedasticity was solved in two ways. First, we took the logarithm of a dependent variable (the number of detected disease cases) to reduce the variance; second, we performed a regression analysis separately for two intervals, depending on the percentage of screening coverage (interval 1 -screening coverage of 0 to 69% and interval 2 -screening coverage of 70 to 100%). The Wald statistics was used to verify the signifi cance of the diff erence between regression coeffi cients and zero.
RESULTS AND DISCUSSION
In the Russian Federation, TSH in newborns is determined in medical and genetic laboratories. There is a fairly strict system of rules, standards, and safety measures that should be met by laboratories analyzing referred samples. By the beginning of screening for CH in 1994, there were only 32 medical genetic laboratories in Russia. Some of them provided services for 7 to 9 nearby regions. The heaviest duties fell on laboratories located in Krasnoyarsk, Stavropol, Khabarovsk, and Nizhny Novgorod. After 10 years, in 2004, the number of laboratories performing the analyses was increased to 48; in 2014, the number of laboratories amounted to 79. Therefore, at the beginning of 2014, only 4 subjects of the Russian Federation did not have their own laboratories (Magadan Region, Nenets and Chukotka Autonomous Districts, Jewish Autonomous Region). After the accession of Crimea in the Russian Federation, the number of laboratories increased to 80 (the laboratory in Crimea is located in Simferopol, and all newborns of the Crimean Federal District, including the city of federal importance Sevastopol, are examined in it).
The incidence of CH and newborn screening coverage in the Russian Federation
The data on the percentage (%) of newborns involved in screening for CH and the number of detected disease cases in the Russian Federation as a whole are presented in Table 1 .
Since 2006, the situation with neonatal screening in the country has changed dramatically. This was primarily associated with implementation of the national priority project "Health". In the last decade (2006-2015), screening for CH has been conducted in all 83 subjects of the Russian Federation (since mid-2014, in 85 subjects). The percentage of newborn screening coverage has also fundamentally changed: this indicator consistently exceeded 90% in most regions and has not fallen below 98% after 2012. The maximum coverage of newborns by screening occurred in 2012 (99.8%).
In the past 10 years (2006-2015), over 350 new cases of the disease have been diagnosed every year due to neonatal screening for CH: from 356 cases in 2006 to 534 cases in 2014. There is a steady tendency towards an annual increase in the number of newly detected CH cases, which is associated, on the one hand, with a rise in births and, on the other hand, with higher coverage of newborns. The incidence of CH in diff erent federal districts of the Russian Federation for the analyzed 18-year period varies from 1:2,379 in the Ural Federal District to 1:4,752 in the North Caucasian Federal District; the coverage of newborns with screening in diff erent districts also varies. The summarized data on coverage of newborns and detected disease cases in federal districts are presented in Table 2 .
The lowest cumulative coverage of newborns by screening for CH is found in the North Caucasian Federal District (81.7%); the lowest incidence of CH is registered in the same federal district (1:4,752). The maximum coverage by screening is observed in the Central Federal District where the highest absolute number of disease cases (1,681) is detected. The absolute number of disease cases in a particular region varies signifi cantly. This is primarily due to diff erent birth rates. For example, in small population regions, there are often no detected CH cases in a particular calendar year. The mean number of annually detected CH cases in each subject of the Russian Federation over the entire study period is 4.76 cases. The largest number of newborns with CH is annually detected in Moscow where, e.g., 85 new cases of the disease were diagnosed in 2009 (this is the maximum number of CH cases in a single subject over the entire observation period).
Analysis of a relationship between the percentage (%) of newborns screened for CH and the number of detected cases
Obviously, incomplete coverage of newborns by the screening procedure may lead to the fact that a certain number of congenital hypothyroidism cases will not be timely diagnosed. The presented results demonstrate a positive tendency in coverage of newborns by screening for CH. Figure shows a diagram of the percentage of newborns not involved, for various reasons, in screening for CH in the analyzed years, with a logarithmic curve with a high percentage of the explained variance (66%) demonstrating a decrease in this indicator that tends to zero.
To investigate a relationship between the percentage of newborn screening coverage and the number of detected cases, we performed a regression analysis of the panel data from 83 subjects of the Russian Federation for 16 years. Before the analysis, we tested a hypothesis about the presence of heteroscedasticity (i.e. an increase in the variance of CH cases with an increase in the percentage of screening coverage) using the Breusch-Pagan test, which confi rmed its presence. The problem of heteroscedasticity was solved in two ways. First, the logarithm of a dependent variable (number of cases) was taken to reduce the variance, and detected cases with zero value were excluded from the analysis, which reduced the number of cases. Second, the regression analysis was conducted separately for two screening coverage intervals (0-69% and 70-100%).
Based on the regression analysis, 6 models were generated; main results of the regression analysis are presented in Table 4 . They indicate that there is the relationship between the absolute number of detected cases and the percentage of newborn screening coverage, both in general and in each of the two selected intervals of screening coverage. An increase in the coverage by one percentage point leads to an increase in the number of annually detected disease cases by more than 3.784 cases in each subject of the Russian Federation.
It should be noted that an increase in screening coverage by 1 percentage point in coverage intervals of 0 to 70% and 70 to 100% increases the number of detected cases by 3.460 and 6.761 cases, respectively. In other words, every percentage point of coverage over 70% is very valuable. A similar situation is observed in the relationship between the logarithm of the number of detected cases and coverage of newborns. The conducted regression analysis indicates that the relationship between the percentage of newborn screening coverage and the number of detected disease cases can hardly be considered linear; therefore, the maximum coverage of all newborns is the goal of neonatal screening for CH. 
CONCLUSION
